FTC, Energized By Androgel, Presses For Patent Settlement Ban
This article was originally published in The Pink Sheet Daily
Executive Summary
In the swirling alliances of the health care reform debate, a press conference by FTC and House Democrats features a consumer who feels he was harmed by the deal between Solvay and generic firms.
You may also be interested in...
FTC Rulemaking Could Be Next (And Last?) Attempt To Curb "Pay-For-Delay"
Potential Federal Trade Commission rule-making looms over the contentious issue of "pay -for-delay" in brand/generic settlements, particularly as the judicial and legislative environments remain uncertain.
FTC Rulemaking Could Be Next (And Last?) Attempt To Curb "Pay-For-Delay"
Potential Federal Trade Commission rule-making looms over the contentious issue of "pay -for-delay" in brand/generic settlements, particularly as the judicial and legislative environments remain uncertain.
Obama Health Reform Plan Uses MA Cuts, Pharma Fees To Close Donut Hole
The Obama administration's proposal on health care reform would phase out the Medicare Part D coverage gap and pay for it through cuts to Medicare Advantage plans and with annual fees on branded biopharmaceutical companies